Preventing familial amyotrophic lateral sclerosis: Is a clinical trial feasible?

Michael G Benatar, Meraida Polak, Samantha Kaplan, Jonathan Glass

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Objective: To evaluate the feasibility of a clinical trial designed to delay or prevent the onset of disease amongst subjects at risk for familial amyotrophic lateral sclerosis (fALS). Background: The success of many agents in prolonging survival in the SOD1 model of ALS has not been translated into effective therapies for patients with ALS. It is our hypothesis that a trial in fALS may reproduce the positive effects seen in fALS animals. Methods: Pedigrees with at least two affected family members were constructed. Unaffected family members were assigned a risk status based on their relationship to affected subjects. Attitudes towards genetic testing were ascertained amongst the at-risk family members. Results: We obtained data about 5544 people (116 families) including 516 subjects with ALS (169 from SOD1 positive families) as well as 1056 subjects "definitely" or "probably" at risk for fALS (335 from SOD1 positive families). In excess of 80% of subjects indicated an interest in participating in a future clinical trial directed at delaying the onset of the disease. Assuming the use of a therapeutic agent that will prolong the time to the onset of fALS by 50%, we estimate that a sample size of between 261 and 610 subjects 'definitely at risk' will be required (power 0.8) depending on whether patients are followed for 10 or 5 years respectively. Conclusions: A clinical trial in fALS may be feasible although such a trial would likely require prolonged follow-up and would require a therapeutic agent with a large clinical effect in order to be adequately powered.

Original languageEnglish
Pages (from-to)3-9
Number of pages7
JournalJournal of the Neurological Sciences
Volume251
Issue number1-2
DOIs
StatePublished - Dec 21 2006
Externally publishedYes

Fingerprint

Clinical Trials
Genetic Testing
Therapeutic Uses
Pedigree
Sample Size
Amyotrophic lateral sclerosis 1
Survival
Therapeutics

Keywords

  • Clinical trial
  • Epidemiology
  • fALS
  • Genetic risk

ASJC Scopus subject areas

  • Aging
  • Clinical Neurology
  • Surgery
  • Developmental Neuroscience
  • Neurology
  • Neuroscience(all)

Cite this

Preventing familial amyotrophic lateral sclerosis : Is a clinical trial feasible? / Benatar, Michael G; Polak, Meraida; Kaplan, Samantha; Glass, Jonathan.

In: Journal of the Neurological Sciences, Vol. 251, No. 1-2, 21.12.2006, p. 3-9.

Research output: Contribution to journalArticle

Benatar, Michael G ; Polak, Meraida ; Kaplan, Samantha ; Glass, Jonathan. / Preventing familial amyotrophic lateral sclerosis : Is a clinical trial feasible?. In: Journal of the Neurological Sciences. 2006 ; Vol. 251, No. 1-2. pp. 3-9.
@article{68d9033b538941539aa9dc9191a28208,
title = "Preventing familial amyotrophic lateral sclerosis: Is a clinical trial feasible?",
abstract = "Objective: To evaluate the feasibility of a clinical trial designed to delay or prevent the onset of disease amongst subjects at risk for familial amyotrophic lateral sclerosis (fALS). Background: The success of many agents in prolonging survival in the SOD1 model of ALS has not been translated into effective therapies for patients with ALS. It is our hypothesis that a trial in fALS may reproduce the positive effects seen in fALS animals. Methods: Pedigrees with at least two affected family members were constructed. Unaffected family members were assigned a risk status based on their relationship to affected subjects. Attitudes towards genetic testing were ascertained amongst the at-risk family members. Results: We obtained data about 5544 people (116 families) including 516 subjects with ALS (169 from SOD1 positive families) as well as 1056 subjects {"}definitely{"} or {"}probably{"} at risk for fALS (335 from SOD1 positive families). In excess of 80{\%} of subjects indicated an interest in participating in a future clinical trial directed at delaying the onset of the disease. Assuming the use of a therapeutic agent that will prolong the time to the onset of fALS by 50{\%}, we estimate that a sample size of between 261 and 610 subjects 'definitely at risk' will be required (power 0.8) depending on whether patients are followed for 10 or 5 years respectively. Conclusions: A clinical trial in fALS may be feasible although such a trial would likely require prolonged follow-up and would require a therapeutic agent with a large clinical effect in order to be adequately powered.",
keywords = "Clinical trial, Epidemiology, fALS, Genetic risk",
author = "Benatar, {Michael G} and Meraida Polak and Samantha Kaplan and Jonathan Glass",
year = "2006",
month = "12",
day = "21",
doi = "10.1016/j.jns.2006.05.069",
language = "English",
volume = "251",
pages = "3--9",
journal = "Journal of the Neurological Sciences",
issn = "0022-510X",
publisher = "Elsevier",
number = "1-2",

}

TY - JOUR

T1 - Preventing familial amyotrophic lateral sclerosis

T2 - Is a clinical trial feasible?

AU - Benatar, Michael G

AU - Polak, Meraida

AU - Kaplan, Samantha

AU - Glass, Jonathan

PY - 2006/12/21

Y1 - 2006/12/21

N2 - Objective: To evaluate the feasibility of a clinical trial designed to delay or prevent the onset of disease amongst subjects at risk for familial amyotrophic lateral sclerosis (fALS). Background: The success of many agents in prolonging survival in the SOD1 model of ALS has not been translated into effective therapies for patients with ALS. It is our hypothesis that a trial in fALS may reproduce the positive effects seen in fALS animals. Methods: Pedigrees with at least two affected family members were constructed. Unaffected family members were assigned a risk status based on their relationship to affected subjects. Attitudes towards genetic testing were ascertained amongst the at-risk family members. Results: We obtained data about 5544 people (116 families) including 516 subjects with ALS (169 from SOD1 positive families) as well as 1056 subjects "definitely" or "probably" at risk for fALS (335 from SOD1 positive families). In excess of 80% of subjects indicated an interest in participating in a future clinical trial directed at delaying the onset of the disease. Assuming the use of a therapeutic agent that will prolong the time to the onset of fALS by 50%, we estimate that a sample size of between 261 and 610 subjects 'definitely at risk' will be required (power 0.8) depending on whether patients are followed for 10 or 5 years respectively. Conclusions: A clinical trial in fALS may be feasible although such a trial would likely require prolonged follow-up and would require a therapeutic agent with a large clinical effect in order to be adequately powered.

AB - Objective: To evaluate the feasibility of a clinical trial designed to delay or prevent the onset of disease amongst subjects at risk for familial amyotrophic lateral sclerosis (fALS). Background: The success of many agents in prolonging survival in the SOD1 model of ALS has not been translated into effective therapies for patients with ALS. It is our hypothesis that a trial in fALS may reproduce the positive effects seen in fALS animals. Methods: Pedigrees with at least two affected family members were constructed. Unaffected family members were assigned a risk status based on their relationship to affected subjects. Attitudes towards genetic testing were ascertained amongst the at-risk family members. Results: We obtained data about 5544 people (116 families) including 516 subjects with ALS (169 from SOD1 positive families) as well as 1056 subjects "definitely" or "probably" at risk for fALS (335 from SOD1 positive families). In excess of 80% of subjects indicated an interest in participating in a future clinical trial directed at delaying the onset of the disease. Assuming the use of a therapeutic agent that will prolong the time to the onset of fALS by 50%, we estimate that a sample size of between 261 and 610 subjects 'definitely at risk' will be required (power 0.8) depending on whether patients are followed for 10 or 5 years respectively. Conclusions: A clinical trial in fALS may be feasible although such a trial would likely require prolonged follow-up and would require a therapeutic agent with a large clinical effect in order to be adequately powered.

KW - Clinical trial

KW - Epidemiology

KW - fALS

KW - Genetic risk

UR - http://www.scopus.com/inward/record.url?scp=33751228383&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33751228383&partnerID=8YFLogxK

U2 - 10.1016/j.jns.2006.05.069

DO - 10.1016/j.jns.2006.05.069

M3 - Article

C2 - 17005203

AN - SCOPUS:33751228383

VL - 251

SP - 3

EP - 9

JO - Journal of the Neurological Sciences

JF - Journal of the Neurological Sciences

SN - 0022-510X

IS - 1-2

ER -